Equities research analysts expect that Inovio Pharmaceuticals, Inc. (NASDAQ:INO) will announce earnings per share of ($0.22) for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Inovio Pharmaceuticals’ earnings. The highest EPS estimate is ($0.13) and the lowest is ($0.29). Inovio Pharmaceuticals posted earnings per share of ($0.28) in the same quarter last year, which indicates a positive year over year growth rate of 21.4%. The business is scheduled to issue its next earnings results on Wednesday, November 8th.

On average, analysts expect that Inovio Pharmaceuticals will report full-year earnings of ($0.90) per share for the current fiscal year, with EPS estimates ranging from ($1.03) to ($0.71). For the next financial year, analysts forecast that the company will report earnings of ($1.18) per share, with EPS estimates ranging from ($1.33) to ($1.04). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that follow Inovio Pharmaceuticals.

Inovio Pharmaceuticals (NASDAQ:INO) last announced its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.21) by $0.08. The business had revenue of $20.41 million during the quarter, compared to the consensus estimate of $16.29 million. Inovio Pharmaceuticals had a negative net margin of 153.46% and a negative return on equity of 63.67%. The firm’s quarterly revenue was up 229.2% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.26) earnings per share.

INO has been the subject of several analyst reports. Aegis reissued a “buy” rating and issued a $14.00 price target on shares of Inovio Pharmaceuticals in a research note on Tuesday, July 18th. Maxim Group increased their price target on shares of Inovio Pharmaceuticals from $10.00 to $12.00 and gave the company a “buy” rating in a research note on Wednesday, May 24th. ValuEngine raised shares of Inovio Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, August 11th. Stifel Nicolaus reissued a “buy” rating and issued a $11.00 price target on shares of Inovio Pharmaceuticals in a research note on Tuesday, April 25th. Finally, Nomura reissued a “buy” rating and issued a $40.00 price target on shares of Inovio Pharmaceuticals in a research note on Monday, May 1st. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $20.78.

COPYRIGHT VIOLATION NOTICE: “-$0.22 EPS Expected for Inovio Pharmaceuticals, Inc. (INO) This Quarter” was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/08/17/0-22-eps-expected-for-inovio-pharmaceuticals-inc-ino-this-quarter.html.

Shares of Inovio Pharmaceuticals (NASDAQ:INO) opened at 5.52 on Thursday. The firm has a 50-day moving average of $6.59 and a 200 day moving average of $6.80. Inovio Pharmaceuticals has a 52 week low of $5.32 and a 52 week high of $9.86. The company’s market cap is $498.05 million.

In other news, Director David B. Weiner sold 8,000 shares of the company’s stock in a transaction that occurred on Thursday, May 25th. The shares were sold at an average price of $8.00, for a total value of $64,000.00. Following the transaction, the director now directly owns 740,956 shares in the company, valued at approximately $5,927,648. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 10.60% of the company’s stock.

Large investors have recently added to or reduced their stakes in the company. BlueCrest Capital Management Ltd acquired a new stake in Inovio Pharmaceuticals during the second quarter worth about $107,000. PNC Financial Services Group Inc. raised its stake in Inovio Pharmaceuticals by 5.0% in the second quarter. PNC Financial Services Group Inc. now owns 21,000 shares of the biopharmaceutical company’s stock worth $164,000 after buying an additional 1,000 shares during the period. Northwestern Mutual Wealth Management Co. acquired a new stake in Inovio Pharmaceuticals during the second quarter worth about $171,000. OxFORD Asset Management LLP acquired a new stake in Inovio Pharmaceuticals during the second quarter worth about $194,000. Finally, UBS Asset Management Americas Inc. raised its stake in Inovio Pharmaceuticals by 0.4% in the second quarter. UBS Asset Management Americas Inc. now owns 25,710 shares of the biopharmaceutical company’s stock worth $202,000 after buying an additional 92 shares during the period. Institutional investors own 22.96% of the company’s stock.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.

Get a free copy of the Zacks research report on Inovio Pharmaceuticals (INO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Inovio Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.